Tgfbr2 Antibody

What is TGFBR2 and what role does it play in cellular signaling?

TGFBR2 is a transmembrane serine/threonine kinase that forms a complex with TGFBR1 to create the non-promiscuous receptor for TGF-beta cytokines (TGFB1, TGFB2, and TGFB3). This receptor complex is critical for transducing TGF-β signals from the cell surface to the cytoplasm. The signaling pathway begins when the constitutively active TGFBR2 phosphorylates and activates TGFBR1, which then phosphorylates SMAD2. The phosphorylated SMAD2 dissociates from the receptor and interacts with SMAD4, forming a complex that translocates to the nucleus to modulate transcription of TGF-β-regulated genes. This represents the canonical SMAD-dependent TGF-β signaling cascade, although TGFBR2 is also involved in non-canonical, SMAD-independent pathways .

TGFBR2 regulates numerous physiological and pathological processes, including:

• Cell cycle arrest in epithelial and hematopoietic cells

• Mesenchymal cell proliferation and differentiation

• Wound healing

• Extracellular matrix production

• Immunosuppression

• Carcinogenesis

What types of TGFBR2 antibodies are available for research applications?

Several types of TGFBR2 antibodies are available for research applications, primarily consisting of polyclonal antibodies generated in rabbits. Based on the search results, these include:

Most commercially available TGFBR2 antibodies target epitopes within the extracellular domain or specific peptide sequences of the protein, enabling detection and/or inhibition of TGFBR2 function in experimental systems .

How do I select the appropriate TGFBR2 antibody for my specific research application?

When selecting a TGFBR2 antibody for your research, consider several key factors to ensure optimal results:

• Application compatibility: Verify that the antibody has been validated for your specific application (WB, IHC, IP, ELISA, etc.). For example, antibody 27212-1-AP has been validated for WB (1:500-1:2000 dilution) and IHC (1:50-1:500 dilution) .

• Species reactivity: Ensure the antibody recognizes TGFBR2 in your experimental species. Some antibodies like CAB11788 show cross-reactivity with human, mouse, and rat samples , while others may be species-specific.

• Epitope location: Consider whether you need an antibody targeting the extracellular domain (for blocking experiments or cell surface detection) or intracellular regions (for signaling studies).

• Validation data: Review published literature and manufacturer validation data, including positive controls. For instance, 27212-1-AP has been positively detected in A549 cells, MCF-7 cells, and COLO320 cells for WB applications .

• Format requirements: Determine if you need unconjugated antibodies or those conjugated to specific tags for direct detection.

• Functional properties: For functional studies, select antibodies that have demonstrated capacity to block TGFBR2 signaling, such as the synthetic antibodies developed for therapeutic applications .

Titrate the antibody in your specific system to determine optimal working concentrations, as recommended dilutions may vary depending on sample type and experimental conditions .

What are the optimal conditions for using TGFBR2 antibodies in Western blot analysis?

For optimal Western blot results with TGFBR2 antibodies, consider the following protocol guidelines:

• Sample preparation:

  • Use appropriate lysis buffers containing protease and phosphatase inhibitors

  • For TGFBR2 detection, validated positive controls include A549 cells, MCF-7 cells, and COLO320 cells

• Gel electrophoresis and transfer:

  • Use 8-10% SDS-PAGE gels for optimal separation of TGFBR2 (calculated MW: 65 kDa; observed MW: 65-80 kDa)

  • Ensure complete transfer to PVDF or nitrocellulose membranes

• Antibody dilutions and incubation:

  • Primary antibody: Use at 1:500-1:2000 dilution as recommended for antibody 27212-1-AP

  • Secondary antibody: Use HRP-conjugated anti-rabbit IgG at manufacturer-recommended dilutions

• Detection and visualization:

  • Look for bands in the 65-80 kDa range, which represents the observed molecular weight for TGFBR2

  • Be aware that variation in band size may occur due to post-translational modifications or different isoforms

• Optimization tips:

  • If background is high, increase blocking time or adjust antibody dilution

  • If signal is weak, extend primary antibody incubation time (overnight at 4°C)

  • Perform antibody titration to determine optimal concentration for your specific samples

Remember that each antibody may require specific optimization, and it is recommended to titrate the reagent in each testing system to obtain optimal results .

How do I optimize immunohistochemistry protocols for TGFBR2 detection in tissue samples?

For optimal immunohistochemical (IHC) detection of TGFBR2 in tissue samples:

• Tissue preparation and antigen retrieval:

  • For TGFBR2 detection, heat-induced epitope retrieval (HIER) is crucial

  • Primary recommendation: Use TE buffer at pH 9.0 for antigen retrieval

  • Alternative method: Citrate buffer at pH 6.0 may also be effective

  • Optimize retrieval time (typically 10-20 minutes) for your specific tissue type

• Blocking and antibody application:

  • Block endogenous peroxidase activity (3% H₂O₂) and non-specific binding (5-10% normal serum)

  • Use TGFBR2 antibody at 1:50-1:500 dilution range

  • Incubate at 4°C overnight for optimal staining

• Detection systems:

  • Use high-sensitivity detection systems (e.g., polymer-based)

  • Include appropriate positive controls (human placenta tissue has been validated)

  • Include isotype controls to assess non-specific binding

• Validation and troubleshooting:

  • Validate staining pattern against known expression patterns

  • If signal is weak, increase antibody concentration or extend incubation time

  • If background is high, optimize blocking or reduce antibody concentration

  • Consider dual staining with cell-type markers to confirm cellular localization

• Quantification approaches:

  • Establish consistent scoring system for TGFBR2 expression (e.g., H-score, Allred score)

  • Consider digital image analysis for objective quantification

  • Include blinded assessment by multiple observers for critical studies

Perform preliminary experiments to establish optimal conditions for your specific tissue type, fixation method, and experimental question .

What methodologies are available for inhibiting TGFBR2 function in experimental models?

Several methodologies are available for inhibiting TGFBR2 function in experimental models, ranging from genetic approaches to pharmacological interventions:

• Antibody-mediated inhibition:

  • Synthetic antibodies targeting the TGFBR2 extracellular domain (ECD) can effectively block TGF-β signaling

  • For example, synthetic antibodies like 5775, 8311, and 8322 have been developed through phage display and affinity maturation processes

  • These antibodies can suppress TGF-β-induced phosphorylation of SMAD2/3, inhibit EMT (epithelial-mesenchymal transition), and reduce cell invasion in cancer models

  • Application protocol: Pretreat cells with antibodies (typically 10-50 μg/ml) for 1 hour before TGF-β stimulation

• Genetic approaches:

  • CRISPR/Cas9-mediated knockout or knockdown

  • Dominant negative TGFBR2 expression

  • siRNA or shRNA targeting TGFBR2 mRNA

• Small molecule inhibitors:

  • Kinase inhibitors targeting the intracellular domain of TGFBR2

  • Combined inhibition of TGF-β receptors type I and II

• Experimental validation:

  • Monitor inhibition efficacy using dual luciferase reporter assays with TGF-β-responsive elements

  • Assess SMAD2/3 phosphorylation by Western blotting

  • Evaluate downstream functional effects (e.g., EMT marker expression, cell migration, invasion)

• In vivo application:

  • Systemic administration of blocking antibodies has shown efficacy in reversing EMT and immune exclusion in tumor models

  • Combination with chemotherapy has demonstrated improved therapeutic response in ovarian cancer models

These inhibitory approaches serve as valuable tools for investigating the role of TGFBR2 in disease pathogenesis and for developing potential therapeutic strategies for conditions involving aberrant TGF-β signaling .

How can I address common issues with TGFBR2 antibody specificity and cross-reactivity?

Addressing specificity and cross-reactivity challenges with TGFBR2 antibodies requires systematic validation and optimization:

• Validation of antibody specificity:

  • Perform knockdown/knockout controls: Compare staining in TGFBR2-depleted versus wild-type samples

  • Use multiple antibodies targeting different epitopes of TGFBR2 to confirm staining patterns

  • Include positive control samples with known TGFBR2 expression (e.g., A549 cells, MCF-7 cells for Western blot)

  • When available, use recombinant TGFBR2 protein as a blocking peptide to confirm specificity

• Addressing cross-reactivity issues:

  • Verify species reactivity before application - for example, CAB11788 reacts with human, mouse, and rat samples , while other antibodies may be more species-restricted

  • Increase stringency of washing steps (longer washes, higher salt concentration)

  • Optimize antibody dilution to reduce non-specific binding

  • Use highly purified antibodies (e.g., antigen-affinity purified) for improved specificity

• Isoform recognition considerations:

  • Be aware that TGFBR2 has multiple isoforms (e.g., isoforms 1, 2, and 3 mentioned in the search results)

  • Confirm which isoforms your antibody recognizes based on the epitope location

  • Consider the functional differences between isoforms when interpreting results

• Storage and handling to maintain specificity:

  • Store antibodies according to manufacturer recommendations (typically at -20°C)

  • Avoid repeated freeze-thaw cycles (aliquot antibodies upon receipt)

  • Some antibodies may contain carrier proteins (e.g., 0.1% BSA) for stability

• Technical controls to include:

  • Secondary antibody-only controls to assess background

  • Isotype controls to evaluate non-specific binding

  • Tissue/cell panels with varying TGFBR2 expression levels

By systematically addressing these aspects, researchers can maximize specificity and minimize cross-reactivity issues with TGFBR2 antibodies in experimental applications.

What factors influence the detection of TGFBR2 in different experimental systems?

Several critical factors can influence TGFBR2 detection across experimental systems:

• Expression level variations:

  • TGFBR2 expression varies significantly across cell types and tissues

  • Expression can be altered in disease states (e.g., downregulated in certain cancers)

  • Dynamic regulation occurs in response to cytokines, growth factors, and other stimuli

  • Consider basal versus stimulated conditions when planning experiments

• Post-translational modifications:

  • Glycosylation contributes to the observed molecular weight variation (65-80 kDa)

  • Phosphorylation status may affect epitope accessibility

  • Subcellular localization changes (membrane to cytoplasmic) during receptor internalization

  • Select antibodies that recognize the relevant form of the protein for your study

• Sample preparation impact:

  • Fixation method and duration significantly affect epitope preservation in IHC

  • For formaldehyde-fixed tissues, antigen retrieval is critical (TE buffer pH 9.0 recommended)

  • Lysis conditions for protein extraction influence membrane protein solubilization

  • Protease inhibitors are essential to prevent degradation during sample preparation

• Technical parameters:

  • Antibody concentration must be optimized for each application (e.g., 1:500-1:2000 for WB, 1:50-1:500 for IHC)

  • Incubation conditions (temperature, duration) affect binding kinetics

  • Detection method sensitivity varies (chemiluminescence vs. fluorescence)

  • Signal amplification systems may be necessary for low-abundance detection

• Species-specific considerations:

  • Epitope conservation across species affects cross-reactivity

  • Antibody validation is often species-specific and should be verified

  • Background binding patterns can differ between species

Understanding these influencing factors allows researchers to design more robust experiments and appropriately interpret results when working with TGFBR2 antibodies.

How should TGFBR2 antibodies be stored and handled to maintain optimal performance?

Proper storage and handling of TGFBR2 antibodies are essential for maintaining their performance and extending their useful lifespan:

• Recommended storage conditions:

  • Store antibodies at -20°C for long-term storage as specified by manufacturers

  • Antibodies are typically provided in stabilizing buffers (e.g., PBS with 0.02% sodium azide and 50% glycerol, pH 7.3)

  • Some antibodies contain carrier proteins (e.g., 0.1% BSA) to maintain stability

  • Avoid storing diluted antibodies for extended periods

• Handling best practices:

  • Aliquot antibodies upon receipt to minimize freeze-thaw cycles

  • Allow antibodies to equilibrate to room temperature before opening to prevent condensation

  • Mix gently by inversion or mild vortexing; avoid vigorous agitation that can denature antibodies

  • Use clean, nuclease-free tubes for aliquoting

  • Wear gloves to prevent contamination with proteases from skin

• Working dilution preparation:

  • Prepare fresh working dilutions on the day of experiment when possible

  • Use high-quality diluents (e.g., TBST with 1-5% BSA or milk for Western blot)

  • Centrifuge stock vial briefly before opening to collect liquid at the bottom

  • If storing diluted antibody short-term, add preservatives (e.g., sodium azide at 0.02%)

• Stability considerations:

  • Most antibodies remain stable for at least one year when stored properly

  • Monitor for signs of degradation (precipitates, loss of activity, increased background)

  • Keep track of freeze-thaw cycles and antibody lot numbers

  • For critical experiments, compare new and previous lots in parallel

• Transportation guidelines:

  • Transport on dry ice for shipping or between facilities

  • For short distances, transport on regular ice if fully thawed and used immediately

  • Avoid prolonged exposure to room temperature

Following these storage and handling recommendations will help ensure consistent antibody performance and reproducible experimental results when working with TGFBR2 antibodies.

How can TGFBR2 antibodies be utilized to study TGF-β signaling pathway dysregulation in disease models?

TGFBR2 antibodies are powerful tools for investigating TGF-β signaling dysregulation in various disease contexts:

• Investigation of TGFBR2 mutations in genetic disorders:

  • TGFBR2 mutations are associated with thoracic aortic aneurysms and dissections (TAADs)

  • Antibodies can be used to assess expression levels and localization patterns of mutant TGFBR2 proteins

  • Compare signaling activity between wild-type and mutant TGFBR2 by measuring SMAD2/3 phosphorylation

  • Analyze mutant-specific alterations in smooth muscle cell phenotype that predispose to vascular pathologies

• Cancer research applications:

  • Examine TGFBR2 expression in tumor samples versus normal tissues using IHC

  • Correlate expression patterns with disease progression, metastasis, and patient outcomes

  • Investigate EMT induction by monitoring TGFBR2 signaling and associated mesenchymal markers

  • Study immune exclusion mechanisms in tumor microenvironments that depend on TGFBR2 signaling

• Therapeutic intervention assessment:

  • Use blocking antibodies to inhibit TGFBR2 signaling in preclinical disease models

  • Monitor effects on downstream pathways via phosphorylation status of signaling molecules

  • Assess phenotypic changes in cell proliferation, differentiation, and apoptosis

  • Evaluate combination therapies, such as TGFBR2 blockade with chemotherapy in ovarian cancer models

• Advanced experimental approaches:

  • Proximity ligation assays to study TGFBR1-TGFBR2 complex formation

  • ChIP-seq with anti-SMAD antibodies following TGFBR2 inhibition to identify altered gene regulation

  • Single-cell analysis of TGF-β response heterogeneity using phospho-specific antibodies

  • In vivo imaging using labeled antibodies to track TGFBR2 expression in animal models

• Mechanistic investigation of non-canonical signaling:

  • Distinguish between SMAD-dependent and SMAD-independent pathways downstream of TGFBR2

  • Study cross-talk with other signaling networks using pathway-specific inhibitors alongside TGFBR2 antibodies

  • Investigate isoform-specific functions, such as the differential activities of isoforms 1, 2, and 3

These advanced applications leverage TGFBR2 antibodies to reveal mechanisms underlying disease pathogenesis and identify potential therapeutic targets in conditions involving aberrant TGF-β signaling.

What are the emerging techniques for developing more selective and potent TGFBR2-targeting antibodies?

Several innovative approaches are being employed to develop next-generation TGFBR2 antibodies with enhanced selectivity and potency:

• Phage display technology and affinity maturation:

  • Phage display libraries enable screening of large numbers of antibody candidates against TGFBR2-Fc fusion proteins

  • The extracellular domain (ECD) of TGFBR2 expressed as a fusion protein with IL-2 signal sequence and human IgG1 Fc domain serves as an effective antigen

  • Affinity maturation through "soft-randomization" of complementarity-determining regions (CDRs) can significantly improve binding affinity

  • This approach has successfully generated antibodies like 5775, which was further optimized to create derivatives with increased efficacy (e.g., 8311, 8322)

• Structural biology-guided antibody engineering:

  • Crystal structures of TGFBR2-ligand complexes inform epitope selection and antibody design

  • Structure-based computational design helps predict and optimize antibody-antigen interactions

  • Site-directed mutagenesis can fine-tune binding properties to specific functional regions of TGFBR2

  • Molecular dynamics simulations help evaluate binding stability and dynamics

• Functional screening approaches:

  • Dual luciferase reporter assays with TGF-β-responsive elements provide quantitative measurement of inhibitory potency

  • Cell-based phospho-SMAD2/3 assays enable rapid evaluation of signaling blockade

  • Screening in disease-relevant cell types (e.g., cancer cell lines, smooth muscle cells) ensures context-appropriate activity

  • High-content imaging platforms allow multiplexed assessment of downstream pathway effects

• Advanced antibody formats and modifications:

  • Bispecific antibodies targeting TGFBR2 and a second target for enhanced specificity or function

  • Fc engineering to modulate effector functions or extend half-life

  • Antibody fragments (Fab, scFv) for improved tissue penetration

  • pH-sensitive antibodies designed for selective binding in tumor microenvironments

• Combination with emerging technologies:

  • CRISPR epitope tagging for improved antibody selection and validation

  • AI-driven antibody design to predict optimal sequences for TGFBR2 binding

  • Single B-cell cloning from immunized animals for novel antibody discovery

  • Display technologies beyond phage display (e.g., yeast, mammalian cell display)

These cutting-edge approaches are driving the development of TGFBR2 antibodies with improved specificity, potency, and therapeutic potential for targeting TGF-β signaling in various disease contexts .

How can researchers evaluate the functional impact of TGFBR2 antibodies in complex biological systems?

Evaluating the functional impact of TGFBR2 antibodies in complex biological systems requires multi-dimensional approaches that assess both molecular signaling and physiological outcomes:

• Cellular signaling analysis:

  • Quantitative assessment of SMAD2/3 phosphorylation kinetics using phospho-specific antibodies

  • Analysis of both canonical (SMAD-dependent) and non-canonical TGF-β signaling pathways

  • Transcriptional profiling (RNA-seq or qRT-PCR) of TGF-β-responsive genes following antibody treatment

  • Protein-protein interaction studies to examine effects on TGFBR1-TGFBR2 complex formation

  • Receptor internalization and trafficking studies using fluorescently labeled antibodies

• Cellular phenotype evaluation:

  • EMT assessment through analysis of epithelial (E-cadherin) and mesenchymal (N-cadherin, vimentin) markers

  • Cell migration and invasion assays to measure functional impact on motility

  • Cell cycle analysis to evaluate effects on proliferation and growth arrest

  • Apoptosis assays to determine impact on cell survival

  • Differentiation studies in relevant cell types (e.g., smooth muscle cells, which show phenotypic alterations in TGFBR2 mutation carriers)

• Tissue and organ-level analyses:

  • Ex vivo tissue culture models treated with TGFBR2 antibodies to assess tissue architecture

  • Organoid systems to evaluate effects in 3D environments that better recapitulate in vivo complexity

  • Histological analysis of extracellular matrix production and organization

  • Multi-parameter immunofluorescence to assess cell-type specific responses within heterogeneous tissues

• In vivo model systems:

  • Tumor xenograft and syngeneic models to evaluate effects on cancer progression and therapy response

  • Assessment of immune cell infiltration and activation in tumor microenvironments

  • Cardiovascular models to study effects on vascular remodeling relevant to TAAD

  • Pharmacodynamic marker analysis to confirm target engagement and pathway modulation

  • Combination therapy studies with standard treatments (e.g., chemotherapy in ovarian cancer models)

• Translational relevance assessment:

  • Correlation of preclinical findings with human patient samples

  • Comparison of antibody effects between normal and disease-associated TGFBR2 variants

  • Evaluation of potential biomarkers for response prediction

  • Assessment of resistance mechanisms that may emerge during treatment

This comprehensive evaluation framework allows researchers to fully characterize the functional impact of TGFBR2 antibodies across scales from molecular interactions to physiological outcomes, facilitating translation to potential therapeutic applications .

What are the potential therapeutic applications of TGFBR2-targeting antibodies in human diseases?

TGFBR2-targeting antibodies show promising therapeutic potential across multiple disease contexts:

• Cancer therapy applications:

  • Reversal of TGF-β-mediated immune suppression in tumor microenvironments

  • Inhibition of EMT to reduce metastatic potential and invasion

  • Sensitization of tumors to chemotherapy, as demonstrated in ovarian cancer models where TGFBR2 blockade improved response to standard treatments

  • Targeting cancer stem cell populations that depend on TGF-β signaling

  • Combination with immune checkpoint inhibitors to enhance anti-tumor immune responses

• Cardiovascular disease interventions:

  • Prevention or treatment of thoracic aortic aneurysms and dissections (TAADs) associated with TGFBR2 mutations

  • Modulation of smooth muscle cell phenotype to prevent pathological vascular remodeling

  • Reduction of fibrosis in cardiac remodeling after myocardial infarction

  • Prevention of intimal hyperplasia following vascular injury

• Fibrotic disorders:

  • Attenuation of fibroblast activation and excessive extracellular matrix production

  • Treatment of pulmonary, hepatic, and renal fibrosis

  • Modulation of wound healing to prevent excessive scarring

  • Targeting tissue-specific fibrotic processes in systemic sclerosis

• Immunological applications:

  • Regulation of inflammatory responses in autoimmune disorders

  • Modulation of regulatory T cell function in transplant rejection

  • Restoration of immune surveillance mechanisms in chronic infections

  • Control of pathological inflammation in inflammatory bowel diseases

• Developmental and regenerative medicine:

  • Modulation of stem cell differentiation pathways for tissue engineering

  • Control of scarring during tissue repair and regeneration

  • Regulation of epithelial-mesenchymal interactions during organogenesis

  • Potential applications in treating congenital disorders associated with TGF-β pathway dysfunction

These therapeutic applications leverage the central role of TGFBR2 in diverse physiological and pathological processes, with emerging evidence supporting the efficacy of targeted antibody approaches in preclinical models .

How might advances in antibody engineering improve the specificity and efficacy of TGFBR2 antibodies?

Advances in antibody engineering are poised to enhance TGFBR2 antibody specificity and efficacy through several innovative approaches:

• Structure-guided antibody optimization:

  • Crystal structure determination of antibody-TGFBR2 complexes enables precise epitope mapping

  • Computational modeling identifies key binding residues for mutagenesis

  • Rational CDR engineering based on structural insights improves binding kinetics

  • Design of antibodies that selectively block specific TGFBR2 interaction sites while preserving others

• Novel antibody formats and modifications:

  • Bispecific antibodies targeting TGFBR2 and tissue-specific markers for enhanced localization

  • Antibody-drug conjugates for targeted delivery of cytotoxic agents to TGFBR2-expressing cells

  • pH-sensitive antibodies that bind selectively in tumor microenvironments

  • Smaller antibody fragments (nanobodies, single-domain antibodies) for improved tissue penetration

  • Engineered Fc domains with optimized effector functions or extended half-life

• Advanced selection technologies:

  • Deep mutational scanning of antibody libraries to identify optimal binding variants

  • Affinity maturation strategies like those used to develop improved anti-TGFBR2 Fabs (e.g., 8311 and 8322 from parent 5775)

  • Phage display with increased stringency to bias selection toward higher affinity clones

  • Single B-cell sequencing from immunized animals to identify naturally occurring high-affinity antibodies

• Tissue-specific targeting strategies:

  • Antibody formatting to enhance blood-brain barrier penetration for CNS applications

  • Tumor-specific delivery systems to minimize off-target effects

  • Conditional activation systems that respond to disease-specific environmental cues

  • Incorporation of tissue-targeting peptides or domains

• Functional selection approaches:

  • High-throughput screening using TGF-β-responsive luciferase reporters

  • Selection based on inhibition of specific downstream pathways (SMAD-dependent vs. SMAD-independent)

  • Evolution of antibodies with desired functional profiles (e.g., blocking ligand binding without affecting receptor dimerization)

  • Development of antibodies that selectively target specific TGFBR2 isoforms (e.g., isoforms 1, 2, or 3)

These engineering advances promise to yield next-generation TGFBR2 antibodies with enhanced therapeutic potential, improved targeting, and reduced off-target effects, potentially expanding their clinical applications across multiple disease contexts.

What emerging research areas might benefit from improved TGFBR2 antibody technologies?

Several cutting-edge research areas stand to gain significant advances from improved TGFBR2 antibody technologies:

• Cancer immunotherapy enhancement:

  • Investigation of TGF-β-mediated immune exclusion mechanisms in "cold" tumors

  • Development of combination therapies involving TGFBR2 blockade and immune checkpoint inhibitors

  • Study of tumor microenvironment remodeling following TGF-β pathway inhibition

  • Investigation of mechanisms by which TGFBR2 blockade improves chemotherapy response, as demonstrated in ovarian cancer models

• Single-cell biology and heterogeneity:

  • Analysis of cell-specific TGF-β signaling responses at single-cell resolution

  • Mapping of TGF-β pathway activity across tissue microenvironments

  • Understanding cellular heterogeneity in response to TGFBR2 blockade

  • Identification of resistance mechanisms to TGF-β pathway inhibition

• Genetic disease mechanisms:

  • Detailed characterization of TGFBR2 mutations in thoracic aortic aneurysms and dissections (TAADs)

  • Investigation of smooth muscle cell phenotypic alterations associated with TGFBR2 mutations

  • Exploration of genotype-phenotype correlations in TGFBR2-associated disorders

  • Development of personalized treatment approaches for patients with specific TGFBR2 variants

• Organoid and 3D tissue models:

  • Study of TGF-β signaling in complex 3D tissue architectures

  • Development of disease-specific organoid models incorporating TGFBR2 mutations

  • Evaluation of drug responses in patient-derived organoids following TGFBR2 blockade

  • Investigation of epithelial-mesenchymal interactions in development and disease

• Regenerative medicine applications:

  • Modulation of TGF-β signaling in tissue engineering applications

  • Control of stem cell differentiation through precise TGFBR2 targeting

  • Regulation of extracellular matrix production in artificial tissues

  • Promotion of functional tissue regeneration without fibrosis

• Novel gene therapy approaches:

  • Development of antibody-guided delivery systems for TGFBR2-targeting gene therapies

  • In vivo gene editing to correct TGFBR2 mutations in affected tissues

  • Antibody-mediated targeting of therapeutic vectors to specific cell populations

  • Combination of antibody therapy with genetic approaches for synergistic effects

These emerging research areas represent the frontier of TGFBR2-related investigation, where improved antibody technologies could enable transformative discoveries and therapeutic advancements .